Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rabeprazole, Amoxicillin, Tetracycline, Furazolidone, and Colloidal Bismuth Pectin
- Development stage
- Phase 4
- Lead developer
- Eisai
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
This is a combination therapy used for the treatment of Helicobacter pylori (H. pylori) infection. The regimen combines multiple mechanisms of action to effectively eradicate H. pylori bacteria, which is a common cause of gastric and duodenal ulcers, gastritis, and is associated with gastric cancer. The combination includes: - Rabeprazole: A proton pump inhibitor that reduces gastric acid production - Amoxicillin: A penicillin-type antibiotic that interferes with bacterial cell wall synthesis - Tetracycline: A broad-spectrum antibiotic that inhibits bacterial protein synthesis - Furazolidone: A nitrofuran antibacterial agent that also has monoamine oxidase inhibitor (MAOI) properties - Colloidal bismuth pectin: A bismuth compound that provides a protective coating in the stomach and has antimicrobial properties This combination represents a modified bismuth quadruple therapy approach for H. pylori eradication, particularly useful in areas with high antibiotic resistance rates.
- Other names
- modified bismuth quadruple therapy
02
Targets
Bacterial RibosomeNTR (Bacterial nitroreductase)ATP4A (Potassium–transporting ATPase alpha chain 1)PBP (Penicillin-binding protein family)NeuraminidaseMAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on Rabeprazole, Amoxicillin, Tetracycline, Furazolidone, and Colloidal Bismuth Pectin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rabeprazole, Amoxicillin, Tetracycline, Furazolidone, and Colloidal Bismuth Pectin.